Analyst Allen Klee from Maxim Group reiterated a Buy rating on WELL Health Technologies Corp (WELL – Research Report) and keeping the price target at C$8.00.
Allen Klee has given his Buy rating due to a combination of factors including WELL Health Technologies Corp’s strong future guidance and strategic initiatives. The company has introduced an optimistic revenue forecast for 2025, projecting a significant increase compared to the previous year. This guidance surpasses both the analyst’s and the market’s expectations, suggesting a robust growth trajectory.
Additionally, WELL Health is expanding its primary clinics in Canada and enhancing its healthcare technology offerings, which are expected to drive further growth. The potential spin-off of its technology solutions and the consolidation of HEALWELL AI results also contribute to the positive outlook. Despite some revenue recognition delays affecting 2024 results, these are anticipated to reverse in 2025, further supporting the Buy rating. The company’s current valuation, trading below peer averages, and its strategic focus on AI and M&A activities, bolster the confidence in its future performance.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$9.00 price target.
WELL’s price has also changed moderately for the past six months – from C$4.510 to C$3.910, which is a -13.30% drop .